Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights plan (the "Rights Plan") to protect
Board Determined Unsolicited Takeover Proposals Significantly Undervalue the CompanyNo Shareholder Action Required at This Time WASHINGTON, April 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the
In a recent sector analysis by Pablo Zuanic of Zuanic & Associates, key trends across four Eastern states are dissected to understand the brand landscape of the cannabis market.
Ross Gerber, the CEO of Gerber Kawasaki Wealth and Investment Management, expressed his skepticism about Musk's management style in light of the Cybertruck delivery delays.
A Boeing engineer has called for the grounding of the entire 787 fleet due to safety concerns. The engineer, Sam Salehpour, is set to testify before Congress on Wednesday.
Bunge Global reveals leadership appointments post-merger, emphasizing a strategic blend of expertise. Led by CEO Greg Heckman and CFO John Neppl, the combined entity appoints Viterra's David Mattiske as Co-Chief Operating Officer.
Rosen to transition to new role as Chief Development Officer for the Company, with a focus on connecting industry-leading organizations and C-Suite talent to Pagaya to help grow its businessPagaya Technologies Ltd.
Vince Tyra's Attempt to Copy Former CEO Glenn Chamandy's Strategy is Fraught with Risk Due to Mr. Tyra's Track Record of Value DestructionMr. Tyra Unveils Underwhelming Margin Guidance, Speculative Spending, Weak Capital